Nektar Therapeutics

NASDAQ:NKTR

Biotechnology

Healthcare
$34.42 -2.04%

-$1.24 today

Market cap
$987.44M
Beta
1.15
P/E (TTM)
-9.3
EPS (TTM)
-$6.39
52W Low $8.27High $109.00

Volume 0.71M

Average 1.00M

NKTR Total Debt

Short-term and long-term borrowings combined.

Nektar TherapeuticsNASDAQ: NKTR

Total Debt · Q2 FY2026 · quarter ended Jun 2026

Total debt rises 41.4% from a year ago

Total debt stood at $135.93M at the end of Q2 FY2026, up 41.4% from a year earlier and down 5.2% from the prior quarter. Over 3 fiscal years it compounded at +4.2% a year.

Context

  • Total debt amounted to 12.4% of total assets at the end of Q2 FY2026, down 33.9 pp from a year earlier.
  • Total debt increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total debt keeps rising in the next quarterly balance sheet after a +41.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$135.93M-5.2% QoQ
Last fiscal yearDec 2025
$148.91M+45.2% YoY
Year agoJun 2025
$96.16M+41.4% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+41.4%——
1 year+45.2%——
3-year CAGR+4.2%——
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
148.91M USD
Year-over-year change
+45.2%
4-year CAGR
+1.0%

Total Debt vs competitors

How NKTR compares with its peers on the latest reported figures

  • Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +41.4% is the highest of 11, against a peer median of -3.6%.
  • Total debt amounts to 12.4% of total assets for NKTR, versus a peer median of 14.5%.
NKTR Competitors
Total Debt for NKTR and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IMCRImmunocore Holdings plcMar 2026$435.68M USD+0.4%+75.0%40.6%
NKTRNektar TherapeuticsJun 2026$135.93M USD+41.4%+4.2%12.4%
RCUSArcus Biosciences, Inc.Jun 2026$114M USD+4.6%-2.3%12.3%
XNCRXencor, Inc.Jun 2026$65.21M USD-4.0%+46.6%9.0%
CHRSCoherus Oncology, Inc.Mar 2026$54.37M USD-79.9%-56.2%20.4%
MGNXMacroGenics, Inc.Mar 2026$36.51M USD-2.6%+45.3%16.8%
ANLAdlai Nortye Ltd.Dec 2025$26.38M USD-3.1%+59.1%76.6%
IPHAInnate Pharma S.A.Dec 2025€22.56M EUR-27.2%-18.9%36.0%
IMTXImmatics N.V.Mar 2026€15.1M EUR-17.9%+2.4%2.8%
CGENCompugen Ltd.Mar 2026$2.93M USD+5.8%+15.4%2.0%
CRVSCorvus Pharmaceuticals, Inc.Mar 2026$834K USD-27.7%-28.8%0.3%
Peer median (excluding NKTR) —-3.6%+8.9%14.5%

Competitors are the stored peer set for NKTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents25.22M88.23M35.28M44.25M15.12M
Short-term Investments708.74M416.75M268.34M210.97M230.64M
Net Receivables22.49M8.4M2.25M1.61M1.78M
Inventory15.8M19.2M16.1M00
Other Current Assets00000
Total Current Assets795.58M545.97M330.7M261.29M266.27M
Property, Plant & Equipment (Net)177.54M85.89M36.86M11.82M5M
Goodwill76.5M76.5M000
Intangible Assets00000
Long-term Investments64.83M025.83M26.09M3.49M
Tax Assets00000
Other Non-current Assets2.74M2.25M4.64M4.65M5.65M
Total Non-current Assets321.61M164.63M67.33M42.56M14.14M
Total Assets1.12B710.6M398.03M303.85M280.41M
Account Payables9.75M12.98M9.85M11.56M10.77M
Short-term Debt000020.5M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities15.74M9.58M5.55M5.55M22.27M
Total Current Liabilities85.2M68.2M51.27M61.4M53.54M
Long-term Debt000063.16M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities226.75M162.93M117.26M99.02M8.63M
Total Non-current Liabilities352.48M275.76M215.78M181.71M137.04M
Total Liabilities437.68M343.96M267.05M243.11M190.57M
Common Stock19K19K19K19K2K
Retained Earnings(2.83B)(3.2B)(3.48B)(3.6B)(3.76B)
Accumulated OCI(4.16M)(6.91M)80K61K17K
Other Stockholders Equity00000
Minority Interest00000
Total Equity679.51M366.64M130.99M60.74M89.83M
Total Debt143.18M131.5M117.78M102.56M148.91M
Net Debt117.96M43.27M82.5M58.31M133.79M

Nektar Therapeutics

NASDAQ:NKTR

Intrinsic Alpha fair value

Locked

Current Price

$34.42

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.